Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.
J. Clin. Oncol., Dec (2012)
Reply to "Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?" Haematologica. 2012;97(11):e45.
Haematologica., Nov;97(11):e46 (2012)
Intracellular Delivery and Trafficking Dynamics of a Lymphoma-Targeting Antibody-Polymer Conjugate.
Mol. Pharm., Nov (2012)
Effect of cationic side-chains on intracellular delivery and cytotoxicity of pH sensitive polymer-doxorubicin nanocarriers.
Nanoscale., Nov;4(22):7012-20 (2012)
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.
Nucl Med Commun., Dec;33(12):1225-31 (2012)
Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers.
Immunotherapy., May;4(5):483-5 (2012)
Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings.
Adv Hematol., 2012:932658 (2012)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Blood., Apr;119(17):3940-50 (2012)
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Haematologica., Jun;97(6):937-42 (2012)
Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.
EJNMMI Res., 1(1):7 (2011)
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Clin. Cancer Res., Dec;17(23):7373-82 (2011)
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
J. Clin. Oncol., Aug;29(22):3023-9 (2011)
Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells.
Mol. Ther., Aug;19(8):1529-37 (2011)
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Blood., Jul;118(3):703-11 (2011)
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.
J. Nucl. Med., Jun;52(6):896-900 (2011)
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Oct;17(10):1537-45 (2011)
â¹â°Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Blood., Jul;118(4):1132-9 (2011)
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.
Leuk. Lymphoma., Jan;52(1):24-33 (2011)
A pretargeted nanoparticle system for tumor cell labeling.
Mol Biosyst., Mar;7(3):742-8 (2011)
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Blood., Nov;116(20):4231-9 (2010)
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
Bioconjug. Chem., Jul;21(7):1225-38 (2010)
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Leuk. Lymphoma., Aug;51(8):1523-9 (2010)
Pretargeted radioimmunotherapy for hematologic and other malignancies.
Cancer Biother. Radiopharm., Apr;25(2):125-42 (2010)
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
J. Immunol., Apr;184(8):4284-94 (2010)
Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.
Cancer., Feb;116(4 Suppl):1126-33 (2010)
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop.
Leuk. Lymphoma., Mar;51(3):390-8 (2010)
Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.
Curr Opin Oncol., Mar;22(2):143-9 (2010)
Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
Blood., Dec;114(27):5454-63 (2009)
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.
Ann. Oncol., Jun;21(6):1196-202 (2010)
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Blood., Dec;114(27):5444-53 (2009)
Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.
Bioconjug. Chem., Oct;20(10):1983-91 (2009)
Treatment of lymphoma with adoptively transferred T cells.
Expert Opin Biol Ther., Nov;9(11):1407-25 (2009)
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.
Blood., Aug;114(6):1226-35 (2009)
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.
Blood., Jun;113(23):5905-10 (2009)
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
Cancer Res., Mar;69(6):2408-15 (2009)
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.
Blood., Apr;113(17):3891-5 (2009)
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
Blood., May;113(20):4903-13 (2009)
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Cancer Res., Jan;69(1):185-92 (2009)
Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.
J. Clin. Oncol., Nov;26(32):5147-50 (2008)
High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
Cancer., Sep;113(6):1344-50 (2008)
Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.
Oncologist., Jun;13(6):657-67 (2008)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Blood., Sep;112(6):2261-71 (2008)
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
Blood., Aug;112(3):830-5 (2008)
Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.
Cancer Biother. Radiopharm., Apr;23(2):181-91 (2008)
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
J. Immunol., May;180(10):7028-38 (2008)
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.
Leuk. Lymphoma., Jun;49(6):1062-73 (2008)
Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
J. Nucl. Med., May;49(5):837-44 (2008)
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz
Blood., Apr;111(8):4048-54 (2008)
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.
Blood., Feb;111(4):2261-8 (2008)
The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.
Bone Marrow Transplant., Dec;40(11):1039-44 (2007)
The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation.
Leuk. Lymphoma., Oct;48(10):1961-7 (2007)
Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies.
Curr. Opin. Hematol., Nov;14(6):632-8 (2007)
Pretargeted radioimmunotherapy for B-cell lymphomas.
Clin. Cancer Res., Sep;13(18 Pt 2):5598s-5603s (2007)
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
Hum. Gene Ther., Aug;18(8):712-25 (2007)
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
Cancer Res., Jun;67(12):5921-8 (2007)
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
Blood., Sep;110(6):2049-56 (2007)
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
J. Clin. Oncol., Apr;25(11):1396-402 (2007)
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.
Blood., Jun;109(11):4980-7 (2007)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
J. Clin. Oncol., Sep;24(25):4143-9 (2006)
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.
Biol. Blood Marrow Transplant., Jul;12(7):697-702 (2006)
A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Cancer Res., Apr;66(7):3884-92 (2006)
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
Blood., Jul;108(1):328-36 (2006)
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
Blood., Mar;107(5):2184-91 (2006)
New treatment options have changed the survival of patients with follicular lymphoma.
J. Clin. Oncol., Nov;23(33):8447-52 (2005)
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Clin. Cancer Res., Jul;11(13):4857-66 (2005)
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.
J. Clin. Oncol., May;23(15):3439-46 (2005)
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Blood., Jun;105(12):4576-82 (2005)
Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.
Clin. Cancer Res., Jan;11(2 Pt 1):787-94 (2005)
Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Bioconjug. Chem., 16(1):131-8 (2005 Jan-Feb)
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
J. Nucl. Med., Jun;45(6):1059-64 (2004)
Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.
Support Care Cancer., Jul;12(7):517-25 (2004)
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Mol. Ther., Apr;9(4):577-86 (2004)
Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism.
Blood., May;103(9):3516-20 (2004)
Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective.
Semin. Oncol., Apr;30(2 Suppl 4):10-21 (2003)
A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex.
Bioconjug. Chem., 13(5):996-1001 (2002 Sep-Oct)
Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.
Bioconjug. Chem., 13(3):611-20 (2002 May-Jun)
A streptavidin-biotin binding system that minimizes blocking by endogenous biotin.
Bioconjug. Chem., 13(3):588-98 (2002 May-Jun)
Radiolabeled antibody therapy of B-cell lymphomas.
Semin. Oncol., Oct;26(5 Suppl 14):58-65 (1999)
Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
Oncology (Williston Park, N.Y.)., Oct;12(10 Suppl 8):63-76 (1998)
Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
Cancer J Sci Am., Jul;4 Suppl 2:S19-26 (1998)
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
J. Clin. Oncol., Feb;16(2):574-8 (1998)
The potential for immunoconjugates in lymphoma therapy.
Hematol. Oncol. Clin. North Am., Oct;11(5):987-1006 (1997)
The role of radioimmunotherapy in bone marrow transplantation.
Curr. Opin. Hematol., Nov;3(6):438-45 (1996)
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
Cancer Res., May;56(9):2123-9 (1996)
Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model.
Cancer Res., Jan;52(1):89-94 (1992)
High dose radiolabeled antibody therapy of lymphoma.
Cancer Res., Feb;50(3 Suppl):1017s-1021s (1990)
Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
J. Clin. Oncol., Aug;7(8):1027-38 (1989)
Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes.
Cancer Res., Apr;48(8):2249-57 (1988)